Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Oleclumab |
Synonyms | |
Therapy Description |
Oleclumab (MEDI9447) is a monoclonal antibody against NT5E (CD73), resulting in activation of an anti-tumor immune response by preventing the conversion of AMP to adenosine in the tumor microenvironment (PMID: 27622077). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Oleclumab | MEDI9447 | Adenosine Targeting 23 CD73 Antibody 12 | Oleclumab (MEDI9447) is a monoclonal antibody against NT5E (CD73), resulting in activation of an anti-tumor immune response by preventing the conversion of AMP to adenosine in the tumor microenvironment (PMID: 27622077). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02503774 | Phase I | Durvalumab Oleclumab | MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors | Completed | USA | AUS | 1 |